EUCTR2005-003789-40-SE进行中（未招募）不适用
A randomized, four-way cross-over, double-blind, controlled study of oral donepezil (2, 5, 10 mg) in patients with moderate to severe obstructive sleep apnea.
Pharmapnea AB0 个研究点目标入组 30 人开始时间: 2005年9月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Eligible for this study are patients who meet each one of the following criteria at the screening visit.
- •-Males and females; age 25 to 65 years
- •-Previously diagnosed OSA defined as an oxygen desaturation (4%) index of 15 or more obtained from a preceding routine outpatient screening recording. The screening study had to encompass at least 6 hours overnight recording of SaO2, respiratory movements (impedance), heart rate, nasal and oral airflow, breathing sounds, and body position.
- •-The patient is able to read and understand the patient information sheet.
- •-The patient has given signed informed consent before any study specific procedures are carried out.
- •-The patient is willing to attend the study appoints in the correct time window.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who meet one or more of the following criteria at the screening visit or at Visit 2 on Day 1 cannot be selected:
- •1.Previous exposure to continuous positive airway pressure (CPAP treatment) or oral devices is allowed but treatment has to be interrupted at least one week before the first study night and throughout the whole study period
- •2.Coronary heart disease
- •3.Previously known or treated cardiac arrhythmia of any type
- •4.Myocardial infarction or stroke within 12 months before study enrolment
- •5.A body weight exceeding Body Mass Index of 32 kgm-2
- •6.Patient has a history of or current abuse or dependence on any substance with abuse potential according to DSM-IV-TRTM. This includes alcohol, hypnotics, and drugs of abuse, but excludes nicotine dependence. A patient who fulfils DSM-IV-TRTM criteria for sustained full remission can be included if he/she, in the investigator’s opinion, is not at risk for drug dependence or abuse.
- •7.Patient has any of the following conditions:
- •a.restless leg syndrome
- •b.severe or acute respiratory failure
- •c.myasthenia gravis
- •d.proneness to muscle spasm or epileptic seizure.
- •8.Use of disallowed recent/concomitant therapy:
- •a.An investigational drug within 3 months prior to screening visit.
- •b.Use of any psychoactive or hypnotic drug (including herbal remedies) or benzodiazepines within 1 week prior to screening visit.
- •c.Depot antipsychotics within 6 months prior to screening.
- •d.Use of antihistamines with sedative properties within 2 weeks prior to screening visit.
- •e.Use of any drug containing opiate or opiate derivatives.
- •f.Use of antiepileptics within 14 days prior to screen visit.
- •g.Serotonin reuptake inhibitors
- •h.Mirtazepin
- •i.Flurazepam or diazepam within 2 weeks prior to screening visit.
- •j.Weight reducing drugs.
- •k.Hormone replacement therapy is allowed when given at least under the last three months with constant dosage
- •9.The patient consumes on average more than 14 units (females) or more than 21 units (males) of alcohol per week on a regular basis (glasses of wine/beer and its equivalent).
- •10.History of severe drug allergy or hypersensitivity, or known hypersensitivity to donepezil.
- •11.Patient has a known positive HIV test or chronic hepatitis B/C.
- •12.Diseases/medication, which, judged by the investigator, could interfere with the assessments of safety, tolerability or efficacy.
- •13.Unstable serious illness and/or serious sequelae thereof, including liver or renal insufficiency, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbances. (If there is history of such disease but the condition has been stable for at least one year and is judged by the investigator not to lead to an unsafe inclusion and not to interfere with the patient’s participation in the study, the patient may be included).
- •14.The patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any other reasons.
- •15.Laboratory values at screening outside the normal ranges, considered by the investigator to be clinically significant. If urine creatinine is out of range, impaired renal function has to be considered.
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, four way cross-over, placebo controlled trial to evaluate the clinical efficacy, onset of action and drug activity at 22-26 hours following the drug intake of Bilastne 20 mg vs placebo and in competition to Cetirizine 10 mg, Fexofenadine 120 mg in reducing symptoms of seasonal allergic rhinitis in grass pollen sensitized volunteers exposed on 2 consecutive days in the Vienna Challenge ChamberEUCTR2006-003004-19-ATFAES Farma S.A.76
进行中（未招募）
不适用
A randomized, double-blind, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathyHypertensionEUCTR2005-000286-19-DKovartis Pharma Services AG24
未知
2 期
Early phase II study of TAC-202 in Japanese cedar pollinosis exposure to antigen in an environmental exposure chamber.Japanese cedar pollinosisJPRN-jRCT2080222167Taiho Pharmaceutical Co., Ltd.130
进行中（未招募）
1 期
A phase IV, randomized, double blind cross-over study to evaluate palatability of Patiromer compared to Sodium Polystyrene Sulfonate in healthy subjectsTreatment of hyperkalaemiaMedDRA version: 21.1Level: PTClassification code 10020646Term: HyperkalaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2019-004696-40-FRVifor (International) Inc.68
进行中（未招募）
不适用
A controlled, randomized, double-blind, cross-over study of the onset of analgesic effect of two formulations of ibuprofen for the treatment of pain after oral surgery.PainMedDRA version: 12.0Level: LLTClassification code 10033371Term: PainEUCTR2009-015589-74-SEycomed Sweden Holding 2 AB140